EcoDrugPlus

Folate Receptor Beta-Like

Ensembl ID : ENSKMAG00000001430
Gene Symbol: LOC108240464
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSKMAG00000019639
Gene Symbol: LOC108240341
2 Cross references
338 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSKMAG00000004176
Gene Symbol: LOC108228737
3 Cross references
320 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSKMAG00000009187
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSKMAG00000019843
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSKMAG00000018424
Gene Symbol: LOC108231107
2 Cross references
160 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSKMAG00000010965
Gene Symbol: LOC108238941
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2-Like

Ensembl ID : ENSKMAG00000008627
Gene Symbol: LOC108248738
2 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-4

Ensembl ID : ENSKMAG00000008593
Gene Symbol: LOC108248737
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-4-Like

Ensembl ID : ENSKMAG00000006029
Gene Symbol: LOC108240585
3 Cross references
69 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Gamma-3-Like

Ensembl ID : ENSKMAG00000014980
Gene Symbol: LOC112449772
2 Cross references
184 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSKMAG00000011066
Gene Symbol: GABRA3
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).